Last edition
News about Clinical Trials
Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress
Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.
Clinical Trials | 30/01/2026 | By News Bureau
SK Bioscience Begins Study of Sarbecovirus Vaccine
SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.
Clinical Trials | 30/01/2026 | By News Bureau
Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.
Clinical Trials | 29/01/2026 | By News Bureau
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
Clinical Trials | 29/01/2026 | By News Bureau
Eisai Submits EMA Application for Once-Monthly Maintenance Dosing of Alzheimer's Drug Lecanemab
BioArctic partner Eisai has filed a Marketing Authorisation Variation with the EMA seeking approval for a once-every-four-weeks IV maintenance dosing regimen for lecanemab in early Alzheimer’s disease.
Clinical Trials | 27/01/2026 | By News Bureau
FIU Researchers Advance Functional Precision Medicine for Hard to Treat Cancers
FIU researchers are advancing functional precision medicine for hard-to-treat cancers, with new funding accelerating drug sensitivity testing to identify personalized, effective therapies beyond conventional genetic approaches.
Clinical Trials | 22/01/2026 | By News Bureau
Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma
At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.
Clinical Trials | 22/01/2026 | By News Bureau
Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.
Clinical Trials | 21/01/2026 | By News Bureau
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Clinical Trials | 20/01/2026 | By News Bureau
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Clinical Trials | 19/01/2026 | By News Bureau | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy